PD patients with a high baseline plasma GFAP (> 76.42 pg/mL) showed a more rapid increase in UPDRS-I (β: 0.237, 95% CI [0.055 to 0.419], p = 0.011) and UPDRS-III scores (β: 0.676, 95% CI [0.023 to 1.330], p = 0.043) and H&Y stage (β: 0.098, 95% CI [0.047 to 0.149], p < 0.001) than those with a low baseline plasma GFAP (≤ 48.36 pg/mL; Fig. 3A–D). The gene discussed is GFAP; the disease is Parkinson disease.